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Abstract
Background: Despite advances in supportive care, sepsis-related mortality remains high, especially in patients with acute
kidney injury (AKI). Erythropoietin can protect organs against ischemia and sepsis. This effect has been linked to activation
of intracellular survival pathways, although the mechanism remains unclear. Continuous erythropoietin receptor activator
(CERA) is an erythropoietin with a unique pharmacologic profile and long half-life. We hypothesized that pretreatment with
CERA would be renoprotective in the cecal ligation and puncture (CLP) model of sepsis-induced AKI.
Methods: Rats were randomized into three groups: control; CLP; and CLP+CERA (5 mg/kg body weight, i.p. administered
24 h before CLP). At 24 hours after CLP, we measured creatinine clearance, biochemical variables, and hemodynamic
parameters. In kidney tissue, we performed immunoblotting—to quantify expression of the Na-K-2Cl cotransporter (NKCC2),
aquaporin 2 (AQP2), Toll-like receptor 4 (TLR4), erythropoietin receptor (EpoR), and nuclear factor kappa B (NF-kB)—and
immunohistochemical staining for CD68 (macrophage infiltration). Plasma interleukin (IL)-2, IL-1b, IL-6, IL-10, interferon
gamma, and tumor necrosis factor alpha were measured by multiplex detection.
Results: Pretreatment with CERA preserved creatinine clearance and tubular function, as well as the expression of NKCC2
and AQP2. In addition, CERA maintained plasma lactate at normal levels, as well as preserving plasma levels of
transaminases and lactate dehydrogenase. Renal expression of TLR4 and NF-kB was lower in CLP+CERA rats than in CLP rats
(p,0.05 and p,0.01, respectively), as were CD68-positive cell counts (p,0.01), whereas renal EpoR expression was higher
(p,0.05). Plasma levels of all measured cytokines were lower in CLP+CERA rats than in CLP rats.
Conclusion: CERA protects against sepsis-induced AKI. This protective effect is, in part, attributable to suppression of the
inflammatory response.
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Introduction
Severe sepsis leads to organ failure and is therefore associated
with high mortality. Organ dysfunction is an independent
prognostic factor for intensive care unit (ICU) mortality [1–3],
which is highest among patients with hepatic dysfunction [4]. In
patients with sepsis and concomitant acute kidney injury (AKI),
ICU mortality can be as high as 70% [5]. Approximately 50% of
all patients with sepsis develop AKI, which is also an independent
predictor of 2-year mortality [5–7]. Various pathophysiological
mechanisms have been proposed to explain sepsis-induced AKI
[1]: vasodilation-induced glomerular hypoperfusion; dysregulated
circulation within the peritubular capillary network; tubular
dysfunction induced by oxidative stress; and inflammatory
reactions by systemic cytokine storm or local cytokine production.
In mice, a lack of anti-inflammatory proteins, such as netrin-1, has
been shown to elevate renal and systemic inflammatory markers,
as well as enhancing ischemia and reperfusion kidney dysfunction;
in such mice, treatment with netrin-1 has been found to restore a
normal phenotype during AKI [8].
Toll-like receptors (TLRs) are the major microbial pathogen
receptors on innate immune cells and have been identified in
various organs, including the kidney. In the kidneys of animals
with sepsis, there is marked upregulation of TLR4 [9], which is
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known to stimulate production of the pro-inflammatory transcrip-
tion factor nuclear factor kappa B (NF-kB) [10]. The activation of
NF-kB plays a central role in the pathophysiology of septic shock
[11,12], inducing systemic cytokine production and thus triggering
mechanisms that depress renal function in response to inflamma-
tory diseases [13–16]. Mice deficient in NF-kB-dependent genes
are resistant to septic shock and sepsis-related mortality [12],
which indicates that inflammatory pathways play an important
role in sepsis-induced organ dysfunction.
Erythropoietin is widely used as a treatment for AKI-induced
anemia because it has anti-apoptotic effects on red blood cells and
their precursors. It also has various extra-hematopoietic effects
involving vasopressor, anti-apoptotic, anti-inflammatory and
immunomodulatory activities [17–22]: reducing oxidative stress
and lipid peroxidation; promoting renal tubular cell regeneration,
vascular regeneration, and neoangiogenesis; mobilizing endothe-
lial progenitor cells; and upregulating expression of endothelial
nitric oxide synthase. In addition, erythropoietin is protective of
various types of cells and tissues [23,24], probably because
erythropoietin receptors (EpoRs) are found in a variety of
locations, including glomerular, mesangial, and tubular epithelial
cells [24–26]. The intracellular domain of the EpoR contains
phosphotyrosines that activate certain molecular cascades, includ-
ing that involving the protein kinase B pathway, which also
stimulates NF-kB activation [22,26]. The EpoR isoforms with
non-erythropoietic effects, such as tissue protection, have a lower
affinity for EPO binding [22]. Therefore, the EPO dose used for
this purpose should be greater than is that used in order to achieve
erythropoietic effects [26].
In recent years, short-term, high-dose administration of EPO
has been shown to ameliorate AKI [18,22–24,26]. Even in chronic
kidney disease, treatment with recombinant human erythropoietin
decreases urinary levels of protein and of biomarkers of renal
injury, as well as reducing levels of markers of oxidative stress. In
addition, treatment with erythropoietin lessens carotid artery
intima-media thickness and reduces brachial-ankle pulse wave
velocity, as well as lowering plasma levels of brain natriuretic
peptide and serum levels of asymmetric dimethylarginine, both of
which have been reported to be associated with cardiovascular risk
factors, such as hypertension, diabetes, dyslipidemia and chronic
kidney disease, and are strong predictors of cardiovascular disease
and progression of chronic kidney disease [27].
Continuous erythropoietin receptor activator (CERA) is a
longer-acting erythropoietin with a half-life of <130 h [28],
compared with #9 h for epoetin (alfa and beta) and <25 h for
darbepoetin alfa [29,30]. In a nonischemic model of diabetic
kidney injury in mice [31], CERA was found to protect renal
function. In a model of cyclosporine A-induced renal and
pancreatic islet cell injury, CERA administration correlated with
increased levels of anti-inflammatory mediators—interleukin (IL)-
10 and transforming growth factor beta 1—in the renal
parenchyma, as well as with preserved islet cell viability [32].
The cecal ligation and puncture (CLP) model provokes
polymicrobial sepsis that mimics many features of human sepsis
[33–36]. In the present study, we used the CLP model to
determine whether CERA protects against tissue damage in sepsis-
induced multi-organ dysfunction, as well as to test the hypothesis
that local renal TLR4 and pro-inflammatory pathways mediate
sepsis-induced multi-organ dysfunction and AKI. We demonstrat-
ed that CERA is protective against sepsis-related AKI and tubular
dysfunction, and that it prevents multi-organ dysfunction.
Although the relationship between TLR4 and NF-kB activation
remains hypothetical, we found indirect evidence that EpoR
activation plays a role in sepsis-mediated inflammation.
Results
CERA Protects against Sepsis-Related AKI and Tubular
Dysfunction
We evaluated three groups of Wistar rats, with or without
CLP-induced polymicrobial sepsis and treated or not with
CERA: control, consisting of untreated rats; CLP, consisting of
untreated rats submitted to CLP; and CLP+CERA, consisting of
rats injected with CERA (5 mg/kg body weight, i.p.) 24 h before
CLP. As expected, CLP rats developed kidney dysfunction,
showing, in comparison with control rats, lower urine volume and
creatinine clearance, as well as higher plasma creatinine levels. In
contrast, CLP+CERA rats showed higher urine volume and
lower plasma creatinine, with consequently higher creatinine
clearance, than did CLP rats (Table 1). Plasma levels of
electrolytes (P, K, and Mg) were higher in CLP rats than in
control rats and CLP+CERA rats, being comparable in the latter
two groups (Table 1).
As shown in Table 1, CLP rats showed significantly lower
urinary excretion of sodium, as well as significantly higher
urinary excretion of urea, than did control and CLP+CERA rats.
There were no significant differences in terms of urinary
excretion of potassium. The marked decrease in urine output
in CLP rats was accompanied by increased urine osmolality,
which was significantly higher than that observed for
CLP+CERA rats.
Renal expression of the Na-K-2Cl cotransporter (NKCC2) was
lower in CLP rats than in CLP+CERA rats and controls
(20.6%63.1% vs. 98.7%67.2% and 95.7%62.5%; p,0.001;
Fig. 1). Similar relationships were observed for renal aquaporin 2
(AQP2) expression (CLP vs. CLP+CERA and control: 36.7%6
4.2% vs. 101.3%63.0% and 96.8%62.6%; p,0.001; Fig. 2).
Table 1. Physiological parameters.
Parameter Control CLP CLP+CERA
UV (ml/day) 15.561.8 4.661.5*,{ 16.363.3
Cr (mg/dl) 0.2260.02 0.3460.03|," 0.2160.02
Ccr (ml N min/100 g BW) 0.7360.05 0.3260.10*,{ 0.7060.07
Na (mEq/L) 15262 14661{ 14962
K (mEq/L) 3.860.1 4.860.3|," 3.760.2
P (mg/dl) 7.760.4 9.260.6{,1 7.060.3
Mg (mg/dl) 1.960.1 2.560.2{ 2.260.2
UOsm (mOsm/kg) 555628 12176287{,1 610647.5
UNaV (mEq/day) 1.8760.16 0.6560.17{,1 1.6860.50
UKV (mEq/day) 0.7560.12 0.9660.17 0.6560.10
UureaV (mg/day) 271.1628 562.5624|," 210.0629
AST (IU/L) 104620 175631*,{ 10567
ALT (IU/L) 37620 70611*,{ 4364
LDH (IU/L) 155621 4736103{,{ 175622
Lactate (mg/dl) 1662 2864*,{ 1261
CLP, cecal ligation and puncture; CERA, continuous erythropoietin receptor
activator; UV, urine volume; Cr, creatinine; Ccr, creatinine clearance; BW, body
weight; UOsm, urinary osmolality; UNaV, urinary excretion of sodium; UKV,
urinary excretion of potassium; UureaV, urinary excretion of urea; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase.
*p,0.01 vs. Control; {p,0.01 vs. CLP+CERA; {p,0.05 vs. Control; 1p,0.05 vs.
CLP+CERA; |p,0.001 vs. Control; "p,0.001 vs. CLP+CERA.
doi:10.1371/journal.pone.0029893.t001
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CERA Prevents Multi-Organ Dysfunction
In CLP+CERA rats, plasma levels of aspartate aminotransferase
and alanine aminotransferase were comparable to those observed
for control rats and were significantly lower than those obtained
for CLP rats (Table 1). In addition, CERA administration
appeared to protect the microcirculation, plasma levels of lactate
and lactate dehydrogenase being significantly lower in
CLP+CERA rats than in CLP rats.
Hemodynamics
At 24 h after CLP, mean arterial pressure was similar across the
groups (Table 2), nor were there any differences among the groups
in terms of hematocrit values. Therefore, neither of these variables
were associated with the development of or protection against AKI
or multi-organ dysfunction in sepsis.
EpoR Expression
As shown in Figure 3, renal EpoR expression was markedly
lower in CLP rats than in control rats (69%62% vs. 100%68%;
p,0.01). Pretreatment with CERA partially inhibited the
downregulation of EpoR (CLP+CERA: 83%64%; p,0.05 vs.
CLP).
TLR4 and NF-kB Expression
Figure 4 shows that renal TLR4 expression was markedly
higher in the CLP group than in the control group (170%67.9%
vs. 100%60.0%; p,0.05), whereas it was lower in the
CLP+CERA group than in the CLP group (120%614.7% vs.
170%67.9%; p,0.05). There was no statistically significant
difference between the CLP+CERA and control groups in terms
of TLR4 expression.
As one of the most important transcription factors in the TLR4
signaling pathway, NF-kB plays a critical role in the pathophys-
iology of sepsis. Figure 5 shows that, at 24 h after CLP, renal NF-
kB expression was significantly higher in CLP rats than in control
rats (158%64.8% vs. 100%60.0%; p,0.01), whereas it remained
completely protected in CLP+CERA rats (110%610.0%; p,0.01
vs. CLP).
Inflammatory Cytokine Levels
At 24 h after CLP, plasma levels of IL-1b, IL-2, IL-6, IL-10,
interferon gamma (IFN-c), and tumor necrosis factor alpha (TNF-
a) were higher in CLP rats than in control rats (Table 3). In the
CLP+CERA rats, the plasma levels of these cytokines were
comparable to those observed for the control animals.
Figure 1. Immunoblots for renal Na-K-2Cl cotransporter, revealing a 146- to 176-kDa band (centered at 150 kDa). Semiquantitative
immunoblots prepared from kidney samples. Densitometric analysis of all samples from control rats, rats submitted to cecal ligation and puncture
only, and rats treated with continuous erythropoietin receptor activator prior to undergoing cecal ligation and puncture. Differences among the
means were analyzed by analysis of variance followed by the Student-Newman-Keuls test. P.0.05 for control vs. CLP+CERA. CLP, cecal ligation and
puncture; CERA, continuous erythropoietin receptor activator; NKCC2, renal Na-K-2Cl cotransporter.
doi:10.1371/journal.pone.0029893.g001
C.E.R.A. in Sepsis-Induced Acute Kidney Injury
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Macrophage Infiltration
Infiltration of the renal interstitium by macrophages and
monocytes, as quantified by the CD68-positive cell counts (Fig. 6),
was significantly higher in the CLP group than in the control group
(7.260.6 cells/mm2 vs. 5.060.3 cells/mm2; p,0.01). The CD68-
positive cell count in the CLP+CERA group (4.060.8 cells/mm2)
was significantly lower that that obtained for the CLP group (p,0.01).
Discussion
In our experimental model of sepsis-induced multi-organ
dysfunction, pretreatment with CERA had striking effects on
various biologic parameters. We found that pre-CLP administration
of CERA protected renal function, as well as minimizing liver injury
and the damage caused by impaired microperfusion. We also
demonstrated that CERA administration protected glomerular
filtration against sepsis-induced impairment. In addition, tubular
function (urinary excretion of sodium and urea, as well as expression
of NKCC2 and AQP2) remained normal in rats pretreated with
CERA. Our data indicate that CERA is renoprotective in sepsis and
suggest that the mechanisms underlying cytoprotection are
mediated by inflammatory responses. We also found that renal
EpoR expression, which was downregulated in this model of sepsis,
was preserved by pretreatment with CERA.
In rats, the CLP procedure creates a realistic model of
polymicrobial sepsis [37]. The fact that patients with sepsis are
also treated with fluid resuscitation and broad-spectrum antibiotics
makes this model even more clinically relevant. Sepsis frequently
leads to multi-organ dysfunction, which includes AKI, one of the
most feared complications in patients with sepsis because it further
worsens prognosis and increases the cost of care [1,38]. It has been
shown that the risk of death is 3.2 times higher in patients with
AKI than in those without [7].
Previous experimental studies have also shown that erythropoi-
etin is renoprotective in sepsis [39]. In the present study, we found
Figure 2. Aquaporin 2 expression was preserved in the rats pretreated with continuous erythropoietin receptor activator.
Semiquantitative immunoblots prepared from kidney samples. Densitometric analysis of all samples from control rats, rats submitted to cecal ligation
and puncture only, and rats treated with continuous erythropoietin receptor activator prior to undergoing cecal ligation and puncture. Differences
among the means were analyzed by analysis of variance followed by the Student-Newman-Keuls test. P.0.05 for control vs. CLP+CERA. CLP, cecal
ligation and puncture; CERA, continuous erythropoietin receptor activator; AQP2, aquaporin 2.
doi:10.1371/journal.pone.0029893.g002
Table 2. Hemodynamic parameters.
Parameter Control CLP CLP+CERA
Hematocrit (%) 41.761.3 40.661.8 37.761.8
MAP (mmHg) 115610 111611 11568
CLP, cecal ligation and puncture; CERA, continuous erythropoietin receptor
activator; MAP, mean arterial pressure.
doi:10.1371/journal.pone.0029893.t002
C.E.R.A. in Sepsis-Induced Acute Kidney Injury
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that CLP decreased urinary excretion of sodium and increased
urinary excretion of urea, as well as significantly increasing urinary
osmolality. Semiquantitative immunoblotting showed that the
expression of AQP2 and NKCC2 was decreased in untreated rats
submitted to CLP. These findings confirm those of other studies,
including that conducted by Grinevich et al. [13], who reported
decreased AQP2 abundance in rats with endotoxemia. An
increase in proximal tubule fluid reabsorption would necessarily
reduce distal delivery. Whether a decrease in tubule fluid flow rate
(resulting from increased proximal reabsorption) directly decreases
AQP2 expression remains to be investigated. In our CLP group,
despite extremely low levels of collecting duct AQP2, urine volume
was low, suggesting that the flow into the collecting ducts was
hindered. Therefore, we can speculate that distal delivery is indeed
diminished in CLP rats, resulting in partial osmotic equilibration,
despite decreased AQP2 expression. In addition, the higher
urinary excretion of urea and lower urine volume resulted in
greater urinary osmolality in the CLP rats.
It has been shown that the expression of AQP2 and NKCC2 in
the renal outer medulla is downregulated in rats with lipopoly-
saccharide-induced sepsis [40]. Activated macrophages express
inducible nitric oxide synthase, the inhibition of which can prevent
NKCC2 downregulation in rats [41]. Therefore, the presence of
activated macrophages is likely associated with the production of
pro-inflammatory mediators and peroxynitrite, as well as with the
regulation of AQP2 and NKCC2 [41]. In addition, it is known
that injection of TNF-a, IL-1b, or IFN-c impairs renal function
and inhibits the expression of renal sodium transporters.
Lipopolysaccharide-induced downregulation of sodium transport-
ers has been shown to be unaffected in cytokine knockout mice
[42]. Furthermore, Ho¨cherl et al. [43] demonstrated that NF-kB
activation plays an important role in downregulating expression of
AQP2 and of vasopressin type 2 receptors in sepsis. Conversely,
the authors showed that NF-kB inhibition ameliorates sepsis-
induced AKI in the CLP model, which is in agreement with our
finding that pre-CLP administration of CERA maintained normal
expression of AQP2 and NKCC2.
It is now known that sepsis is a highly heterogeneous clinical
condition. Hypotension and ischemic insult are no longer
considered the main determinants of AKI. In rodents, the features
of sepsis-induced AKI range from normal histology to generalized
renal inflammation [42]. Renal biopsies of patients with sepsis
often reveal leukocyte infiltration [1,44]. Experimental studies
have revealed that sepsis induces leukocyte infiltration into the
glomerular capillaries, as well as apoptosis of glomerular
endothelial cells [1,45]. Similarly, we demonstrated that, in our
Figure 3. Erythropoietin receptor expression was partially protected in the rats pretreated with continuous erythropoietin receptor
activator. Semiquantitative immunoblots prepared from kidney samples. Densitometric analysis of all samples from control rats, rats submitted to
cecal ligation and puncture only, and rats treated with continuous erythropoietin receptor activator prior to undergoing cecal ligation and puncture.
Differences among the means were analyzed by analysis of variance followed by the Student-Newman-Keuls test. p.0.05 for control vs. CLP+CERA.
CLP, cecal ligation and puncture; CERA, continuous erythropoietin receptor activator; EpoR, erythropoietin receptor.
doi:10.1371/journal.pone.0029893.g003
C.E.R.A. in Sepsis-Induced Acute Kidney Injury
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CLP rats, there was considerable macrophage infiltration into the
renal interstitium, and no such infiltration was observed in our
control or CLP+CERA rats.
Sepsis-induced AKI seems to be an inflammatory condition in
which hemodynamics play only a small role. In the present study,
there were no pronounced sepsis-induced hemodynamic changes
in either CLP group. Mean arterial pressure did not differ among
the groups. This raises the hypothesis that hemodynamic changes
play no role in CERA protection against multi-organ dysfunction.
In the present study, rats receiving pre-CLP treatment with
CERA showed higher renal EpoR expression than did untreated
rats submitted to CLP, suggesting that the protective effects of
CERA are related to cellular EpoR activation. The pretreated rats
also showed attenuated expression of TLR4.
The major physiological function of erythropoietin is the
induction of erythropoiesis [39]. Anemia is quite common in
critically ill patients, especially in those with AKI [46]. In such
patients, erythropoiesis is impaired as a consequence of blunted
erythropoietin production and the direct inhibitory effects of
inflammatory cytokines [46]. One plausible hypothesis to explain
this phenomenon is that cytokines diminish EpoR activation,
reducing the effect of erythropoietin. However, it remains unclear
whether augmented EpoR activation leads to reduced TLR4
expression or inhibition of inflammatory molecules permits higher
EpoR expression.
Kalakeche et al. demonstrated that TLR4 knockout mice showed
only minimal endotoxin uptake at all time points, indicating that the
endotoxin pathway is TLR4-dependent [47]. Continued stimula-
tion of TLRs can lead to immune cell apoptosis, which results in
immunosuppression, a late-phase trait of sepsis [48,49].
In animal models of septic shock, as in patients with sepsis, NF-
kB activity has been found to be markedly increased in various
organs [12]. In patients with sepsis, higher levels of NF-kB activity
are associated with higher mortality rates and worse clinical
outcomes [12]. Mice deficient in NF-kB-dependent genes are
resistant to septic shock and sepsis-induced mortality [12].
Inhibition of NF-kB activation ameliorates sepsis-induced myo-
cardial dysfunction and vascular derangement, as well as inhibiting
the expression of multiple pro-inflammatory genes, reducing tissue
neutrophil infiltration, and preventing microvascular endothelial
leakage. Inhibition of NF-kB activation therefore prevents multi-
organ dysfunction and improves survival in rodent models of septic
shock [12]. Studies employing the CLP model have shown that
inhibition of NF-kB activation significantly improves survival [6].
Local inflammation within the kidney is increasingly recognized
as a factor contributing to inflammatory injury in remote organs
Figure 4. Immunoblots reacted with anti-Toll-like receptor 4 antibody (1:100), revealing an 89-kDa band. Semiquantitative
immunoblots prepared from kidney samples. Densitometric analysis of samples from control rats, rats submitted to cecal ligation and puncture only,
and rats treated with continuous erythropoietin receptor activator prior to undergoing cecal ligation and puncture. Differences among the means
were compared by analysis of variance followed by the Student-Newman-Keuls test. p.0.05 for control vs. CLP+CERA. CLP, cecal ligation and
puncture; CERA, continuous erythropoietin receptor activator; TLR4, Toll-like receptor 4.
doi:10.1371/journal.pone.0029893.g004
C.E.R.A. in Sepsis-Induced Acute Kidney Injury
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[1,50]. An AKI-induced increase in IL-6 levels triggers IL-10
production by Kupffer cells in the liver [50–54], resulting in
kidney-liver crosstalk, a hallmark of multi-organ dysfunction. The
pro-inflammatory cytokines TNF-a and IL-8 promote apoptosis
via the NF-kB pathway and amplify liver injury [50,55–57].
During sepsis, NF-kB is known to be activated in many organs,
having potent effects on downstream signaling pathways and tissue
injury [12]. Accordingly, we found that plasma levels of IL-1b,
TNF-a, IFN-c, IL-2, IL-6, and IL-10 were increased in our CLP
group. In addition, there was pronounced liver injury in our CLP
rats, and that injury was attenuated in the CLP+CERA rats.
Damage to the microvascular endothelium and endothelial
dysfunction cause impaired perfusion in multiple organs and
generate hyperlactatemia, thereby contributing to the morbidity
and mortality associated with sepsis. Although hyperlactatemia is
often accompanied by hemodynamic instability, it can also occur
under stable hemodynamic conditions, in which case it is
considered to be due to occult hypoperfusion [58]. In CLP-
induced sepsis, erythropoietin can increase capillary perfusion in
skeletal muscle [59]. We found that arterial lactate levels were
markedly elevated in the CLP group, an alteration that was
effectively prevented by pretreatment with CERA.
In the study known as the EARLYARF trial [60], erythropoietin
was not found to protect against AKI in ICU patients. This
discrepancy could be attributable to various factors. Patients were
screened for AKI risk by determination of the urinary concentrations
Figure 5. Immunoblots reacted with anti-nuclear factor kappa B antibody (1:500), revealing a 65-kDa band. Semiquantitative
immunoblots prepared from kidney samples. Densitometric analysis of samples from control rats, rats submitted to cecal ligation and puncture only,
and rats treated with continuous erythropoietin receptor activator prior to undergoing cecal ligation and puncture. Differences among the means
were compared by analysis of variance followed by the Student-Newman-Keuls test. p.0.05 for control vs. CLP+CERA. CLP, cecal ligation and
puncture; CERA, continuous erythropoietin receptor activator; NF-kB, nuclear factor kappa B.
doi:10.1371/journal.pone.0029893.g005
Table 3. Effects of continuous erythropoietin receptor
activator on plasma levels of pro-inflammatory cytokines at
24 h after cecal ligation and puncture.
Variable Control CLP CLP+CERA
IL-1b (pg/ml) 50612 9856399 5266193
TNF-a (pg/ml) 54612 6267 37610
IFN-c (pg/ml) 5226240 16136631 11186652
IL-2 (pg/ml) 3668 74618 29610
IL-6 (pg/ml) 291665 532680* 237644
IL-10 (pg/ml) 9660 5276211 348696
CLP, cecal ligation and puncture; CERA, continuous erythropoietin receptor
activator; IL, interleukin; TNF-a, tumor necrosis factor alpha; IFN-c, interferon
gamma.
*p,0.05 vs. CLP+CERA.
doi:10.1371/journal.pone.0029893.t003
C.E.R.A. in Sepsis-Induced Acute Kidney Injury
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of two biomarkers, gamma-glutamyl transpeptidase and alkaline
phosphatase. Although the gamma-glutamyl transpeptidase 6
alkaline phosphatase product was efficient in predicting poorer
outcomes, its predictive value for AKI was poor. The conclusions
regarding the development of AKI in the ICU were based on a post
hoc analysis, in which all patients with AKI, regardless of the cause,
were evaluated as a group. Therefore, we believe that the results of
the EARLYARF trial are not definitive, and that further studies are
needed in order to investigate the protective effect of erythropoietin
against AKI in humans.
Our data indicate that CERA protects against multi-organ
dysfunction, and that this protective effect is, in part, attributable
to inhibition of the inflammatory response. We hypothesize that
CERA decreases NF-kB expression via the TLR4 pathway,
thereby inhibiting macrophage infiltration into the renal intersti-
tium and decreasing systemic production of inflammatory
cytokines. In addition, our findings provide indirect evidence that
EpoR activation plays a role in sepsis-mediated inflammation.
This could have real clinical implications for patients with sepsis,
who might benefit from treatment with CERA, which has no effect
on hematocrit or mean arterial pressure and could represent a
feasible method of tissue protection in such patients.
Materials and Methods
Animals and Induction of Sepsis
The study was approved by the Research Ethics Committee of
the University of Sa˜o Paulo School of Medicine. All procedures
were performed in accordance with the National Research
Council Guide for the Care and Use of Laboratory Animals
[61]. The Research Ethics Committee of Medical School of Sa˜o
Paulo University aproved our protocol numbered 308/10, in
november 2010.
Male Wistar rats (200–250 g), obtained from the animal facility
of the University of Sa˜o Paulo School of Medicine, were fed a
normal diet and given ad libitum access to water. The rats were
divided into three groups: control (n = 11), consisting of untreated
rats; CLP (n = 7), consisting of untreated rats submitted to CLP;
and CLP+CERA (n = 9), consisting of rats injected with CERA
(5 mg/kg body weight, i.p.; Roche Diagnostics, Penzberg,
Germany) 24 h before CLP.
The CLP procedure involved exposing a 2-cm section of the cecum,
which was ligated with a cotton suture distal to the ileocecal valve
and punctured twice on its antimesenteric border with a 16-gauge
needle. The cecum was then squeezed to expel a small amount of
fecal material. The bowel was returned to the abdominal cavity,
and the abdominal wall incision was closed. To ensure adequate
fluid resuscitation, each animal received an injection of 0.15 M
NaCl (25 ml/kg body weight, i.p.) immediately after the
procedure. Additional fluid therapy (0.15 M NaCl, 25 ml/kg
body weight, i.p.) was started at 6 h after CLP and then repeated
every 12 h, as was antibiotic therapy with imipenem/cilastatin
(14 mg/kg body weight, i.p.; Merck Sharp & Dohme, West Point,
PA, USA).
Metabolic Cage Studies and Hemodynamic Analysis
After CLP, all rats were moved to individual cages and
maintained on a 12/12-h light/dark cycle (with ad libitum access
to water only, no food provided). After 24-h urine samples had
been collected, rats were anesthetized with pentobarbital sodium
(50 mg/kg body weight) and placed on a temperature-regulated
surgical table. A PE-60 catheter was inserted into the right carotid
artery to record mean arterial pressure. Blood samples were
collected by aortic puncture. Organs were then perfused with
phosphate buffered saline (0.15 M NaCl and 0.01 M phosphate
buffer, pH 7.4), and the kidneys were immediately removed. Some
kidneys were frozen in liquid nitrogen and stored at 270uC for
subsequent immunoblotting. For immunohistochemical analysis,
kidneys were immersed in methacarn (60% methanol, 30%
chloroform, and 10% acetic acid), after which kidney fragments
were embedded in paraffin and cut into 4-mm sections.
Analysis of Blood and Urine
Urine and blood samples were centrifuged, after which the
supernatant was aliquoted and stored at 270uC for subsequently
analysis. Venous plasma lactate and bicarbonate were measured
with a blood gas analyzer (Radiometer Medical, Copenhagen,
Denmark). Urine osmolality was determined using a vapor
pressure osmometer (model 5520; Wescor, Logan, UT, USA).
We measured plasma and urinary levels of creatinine using
kinetic techniques, plasma Mg2+ levels using automated colori-
metric assay, and plasma P levels using automated enzymatic
colorimetric assay. Plasma and urinary levels of other electrolytes
were measured with ion-selective electrodes (NOVA Biomedical,
Waltham, MA, USA). Plasma levels of liver enzymes, lactate
dehydrogenase and urea were measured with automated kinetic
methods.
Antibodies and Reagents
Peptide-derived rabbit polyclonal antibody to NKCC2 was
kindly supplied by Dr. M. Knepper (National Heart, Lung, and
Blood Institute, National Institutes of Health, Bethesda, MD,
Figure 6. Number of CD68-positive cells/0.087 mm2 field in the tubulointerstitium at 24 h after CLP. A, photomicrographs of
immunohistochemical staining in control rats, rats submitted to cecal ligation and puncture only, and rats treated with continuous erythropoietin
receptor activator prior to undergoing cecal ligation and puncture (magnification,640). B, Graphic representation of CD68-positive cell counts. Data
are mean6SEM. p.0.05 for control vs. CLP+CERA. CLP, cecal ligation and puncture; CERA, continuous erythropoietin receptor activator.
doi:10.1371/journal.pone.0029893.g006
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USA). We obtained peptide-derived polyclonal antibodies to
EpoR (M-20), TLR4, NF-kB, AQP2, and actin from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Preparation of Kidney Samples
Kidney fragments were homogenized in ice-cold isolation
solution (200 mM Mannitol, 80 mM Hepes, and 41 mM
potassium hydroxide, pH 7.5) containing protease inhibitors
(protease inhibitor cocktail; Sigma, St. Louis, MO, USA) using a
Teflon pestle glass homogenizer (Schmidt and Co., Frankfurt am
Main, Germany). The homogenates were centrifuged at low speed
(3000 g) for 15 min at 4uC to remove nuclei and cell debris.
Electrophoresis and Immunoblotting
Kidney samples were run on 12.5% polyacrylamide minigels
(for AQP2 and EpoR), 10% polyacrylamide minigels (for NF-kB),
or 8% polyacrylamide minigels (for NKCC2 and TLR4). After
transfer by electroelution to nitrocellulose membranes (Hybond-P;
GE Healthcare, Piscataway, NJ, USA), blots were blocked for 1 h
with 5% milk and 0.1% Tween 20 in Tris-buffered saline (24.2 g/
L Tris, 29.2 g/L NaCl, 3.36 g/L ethylenediaminetetraacetic acid)
and then incubated overnight with the antibodies to AQP2
(1:5000), TLR4 (1:100), NF-kB (1:500), NKCC2 (0.12 mg/ml),
and EpoR (1:1000). The labeling was visualized with horseradish
peroxidase-conjugated secondary antibody (anti-rabbit IgG, dilut-
ed 1:2000, and anti-goat IgG, diluted 1:10,000, Sigma) in the
enhanced chemiluminescence detection system (GE Healthcare).
Renal Expression Analysis
The enhanced chemiluminescence films were scanned with
National Institutes of Health ImageJ software. Antibody expres-
sion was quantified through densitometry, and the bands were
normalized to actin expression.
Immunohistochemistry
For CD68 immunostaining, samples were processed in 4-mm
paraffin sections. After deparaffinization, endogenous peroxidase
activity was blocked with 0.3% H2O2 in water for 10 min at room
temperature. Sections were then subjected to incubation overnight
at 4uC with CD68 antibody (1:100). This was followed by
incubation with biotinylated mouse anti-rat IgG for 30 min at
room temperature. The reaction product was detected with
avidin-biotin-peroxidase complex (Vector Laboratories, Burlin-
game, CA, USA). The color reaction was developed with 3,3-
diaminobenzidine (Sigma), and the sections were counterstained
with methyl green [62].
To obtain the mean numbers of infiltrating CD68-positive cells
in the renal cortical tubulointerstitium, all fields (0.087 mm2 each)
were evaluated and the mean counts per kidney were calculated.
Cytokine Analysis
To determine plasma levels of IL-1b, IL-2, IL-6, IL-10, IFN-c,
and TNF-a, we used a Bio-Plex cytokine assay kit (Rat 9-Plex; Bio-
Rad, Hercules, CA, USA). The assay was read on the Bio-Plex
suspension array system, and the data were analyzed with Bio-Plex
Manager software, version 4.0 [63].
Statistical Analysis
Values are presented as means6standard error of the mean.
Comparisons between groups were made by unpaired t-test.
Comparisons among groups were made by analysis of variance
followed by Student-Newman-Keuls multiple comparisons test.
Values of p,0.05 were considered significant.
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